Biotech stocks to buy now reflect a more dynamic shift in investor focus of late. Over the past few years, the biotech space attracted plenty of investor interest, driven by the Covid-19 pandemic. Global vaccine sales for the crippling virus were upwards of $142 billion from 2020 to 2023. The vaccine rollout was hugely successful across the globe, especially in countries like the U.S., U.K. and Germany. That said, here are three compelling biotech stocks that fit the bill and have the potential to brighten ...

Gene-editing pioneer CRISPR Therapeutics (CRSP 1.22%) stands out in this regard. Despite serious doubt from many in the scientific community, the biotech successfully advanced its gene-edited therapy Casgevy through clinical trials and subsequently won regulatory approvals in several territories such as the U.S., U.K., the European Union, and the Kingdom of Saudi Arabia for both sickle cell disease (SCD) and transfusiondependent beta-thalassemia (TDT). Morningstar analyst Rachel Elfman recently placed a $11 ...

CRISPR Therapeutics (CRSP) In Q1 of 2024, the company reported a net loss of $116.6 million, a significant increase from the prior year's $53 million. This was due to CRSP's strategic investments in R&D and market expansion for Casgevy. Despite this, the firm boasts a robust cash reserve of approximately $2.1 billion, underpinning its capacity for sustained growth and further drug approvals expected in the next two to three years. Vertex Pharmaceuticals (NASDAQ:VRTX) is known for its pioneering cystic fibro ...

Gene editing is a game-changer. With it, we can remove cells from your body, edit them, and then reintroduce them back into the body. All to treat cancers, blood issues, blindness, cystic fibrosis, and muscular dystrophy. All of which is creating substantial opportunities for some of the leading gene editing stocks. Plus, At the moment, there are about 7,000 diseases caused by genetic disorders. All of which occur when a mutation affects your genes. Or, when you have the wrong amount of genetic material, as ...

Heading into today, shares of the company had gained 2.02% over the past month, lagging the Medical sector's gain of 2.32% and the S&P 500's gain of 3.22% in that time. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$5.51 per share and revenue of $89.43 million, indicating changes of -184.02% and -75.91%, respectively, compared to the previous year. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investor ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market pri ...

Investors will be eagerly watching for the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.37 per share, which would represent a year-over-year decline of 39.8%. Our most recent consensus estimate is calling for quarterly revenue of $8.39 million, down 88.02% from the year-ago period. Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Z ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Company Conference Call June 11, 2024 9:20 AM ET Company Participants Sam Kulkarni - Chief Executive Officer Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Good afternoon everyone, thank you for joining us. Really pleased to have Sam Kulkarni, CEO of CRISPR Therapeutics here with us. Sam, perhaps to start here, you have a couple of verticals - you have cancer, ex-vivo non-cancer, regenerative medicine, and in vivo verticals. Can you discus ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this company have returned +7.8% over the past month versus the Zacks S&P 500 composite's +2.9% change. The Zacks Medical - Biomedical and Genetics industry, to which CRISPR Therapeutics belongs, has gained 1.2% over this period. Now the key question is: Where could the stock be headed in the near ...

A month has gone by since the last earnings report for CRISPR Therapeutics AG (CRSP) . Shares have added about 12% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is CRISPR Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Q1 Loss Narrower-Than-Expected, Sa ...